发明名称 |
METHODS FOR PREVENTING TOXIC DRUG-DRUG INTERACTIONS IN COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS |
摘要 |
Methods are disclosed for preventing toxic drug-drug interactions during combination cancer therapy with a drug that is an anti-ErbB3 agent, such as an anti-ErbB3 antibody, together with a drug that is a tyrosine kinase inhibitor and/or a drug that binds to alpha- 1 acid glycoprotein (e.g., erlotinib). Health care practitioners obtaining any one of the drugs are warned that when co-administering the drug that is an anti-ErbB3 agent with either or both of a drug that is a tyrosine kinase inhibitor and a drug that binds to alpha- 1 acid glycoprotein, at least one of the co-administered drugs should be administered using a reduced dosage to prevent toxicity. In a reduced dosage, the amount of drug administered per unit time is reduced as compared to a dose that would be administered if the drug was administered as monotherapy. The reduced dosage can be, for example, a reduced drug dose or a reduced drug dosing frequency, or both. Compositions useful in practicing the disclosed methods are also provided. |
申请公布号 |
CA2833554(A1) |
申请公布日期 |
2012.11.15 |
申请号 |
CA20122833554 |
申请日期 |
2012.05.04 |
申请人 |
MERRIMACK PHARMACEUTICALS, INC. |
发明人 |
ONSUM, MATTHEW DAVID;NIYIKIZA, CLET;MOYO, VICTOR;KUBASEK, WILLIAM |
分类号 |
A61K39/395;A61K38/16;A61K38/17;A61P35/00 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|